Puro Risk Insights Blog
Our blog is an educational hub for clear and timely insights on the cannabis and hemp industry.
We simplify insurance topics regulatory updates and real world risks into easy to understand content for operators at every stage.
From cultivation to retail we provide practical guidance coverage education and market insights to help you stay compliant protected and informed so you can make smarter and more confident decisions.
ON THE BLOG
CATEGORIES
FEATURED POST
Recent Industry Updates
All Articles
Browse our complete collection of cannabis and hemp insights below. This page brings together all published articles covering policy and regulation, business and economy, legal and justice, industry innovation, and culture and community. Each post is created to educate and inform operators and industry stakeholders by breaking down complex topics into clear, practical insights. Scroll down to explore the full library and stay informed on the issues shaping the industry.
A Federal Cannabis Commission Signals Progress, Not Instant Legalization
A proposed federal cannabis legalization commission signals that lawmakers are seeking a real national framework. While it does not mean immediate legalization, it marks continued forward movement in federal cannabis policy.
U.S. Cannabis Markets Continue to Reshape as Federal Policy Evolves
Behind federal rescheduling headlines, U.S. cannabis markets are still experiencing license contraction and consolidation. Operators are shifting focus toward efficiency and long-term sustainability as the industry matures.
Industry and Advocacy Groups React to Federal Cannabis Rescheduling
Industry leaders and reform advocates welcomed federal cannabis rescheduling as historic, while stressing that major issues remain unresolved. The response highlights both progress and the continued need for criminal justice and state federal alignment reforms.
Federal Policy Shift Opens the Door to Clearer CBD and Hemp Regulation
Federal cannabis rescheduling has opened the door to clearer regulation of CBD and hemp-derived cannabinoids. New frameworks could shape product standards, labeling, and oversight, creating both opportunity and responsibility for businesses.
Cannabis Stocks Swing Sharply After Federal Rescheduling Decision
Cannabis stocks saw sharp swings after federal rescheduling became official, reflecting how investor sentiment continues to drive short term market behavior. The volatility highlights the gap between policy progress and immediate financial impact.
Cannabis Officially Moves to Schedule III Under Federal Law
The United States has officially moved cannabis to Schedule III, acknowledging accepted medical use and reducing long standing federal barriers. While cannabis remains federally illegal, the shift opens new pathways for research, healthcare integration, and industry stability.
Cannabis Businesses Still Face Banking Barriers Despite Federal Reclassification
Despite federal reclassification, cannabis businesses still face major barriers accessing traditional banking services. Large financial institutions remain cautious, forcing operators to rely on smaller lenders and alternative financing.
Texas Original Expands Medical Cannabis Production With Major New Campus
Texas Original has opened a new 75,000 square foot medical cannabis production campus, significantly expanding cultivation, processing, testing, and distribution. The move signals serious commercial scaling in Texas following expanded patient eligibility under House Bill 46.
New York Seed to Sale Lawsuit Could Change Cannabis Compliance Statewide
A New York cannabis processor has filed a lawsuit challenging the state’s requirement for item level seed to sale tracking. The case could influence compliance costs, technology choices, and enforcement practices across licensed markets.
What Schedule III Reclassification Could Change for Cannabis in the United States
If cannabis moves to Schedule III, federal barriers around research, medical development, banking, and penalties could ease significantly. While cannabis would remain federally regulated, the change could unlock long awaited pathways for growth and stability.
Disclaimer: All content on this site is for informational and educational purposes only. We share news, insights, and our own interpretations but do not claim ownership of third-party content, always crediting original sources with links. Views expressed in shared content do not necessarily reflect our own. For accurate and current information, please consult the original publisher.
Ready to review your cannabis coverage?
Call us on (323)905-3396
or growth@cannashield.io

Trulieve and Cronos have each gained roughly 27 percent in 2026 while reporting stronger operating results. The broader signal is that public market attention is increasingly rewarding cash generation, improving margins, liquidity, and measurable revenue growth.